MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2025.115688

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2025

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.

Hieken Tina J, Zahrieh David, Flotte Thomas J, Dronca Roxana S, Domingo-Musibay Evidio, Nelson Garth D, Strand Carrie A, Kottschade Lisa A, Montane Heather N, Piltin Mara A, Chen Ruqin, McWilliams Robert R, Jakub James W, Khariwala Samir S, Dudek Arkadiusz Z, Johnson Jeffrey E, Markovic Svetomir N, Dimou Anastasios, Tasche Kendall K, Block Matthew S

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: Neoadjuvant ± adjuvant immunotherapy improves event-free survival (EFS) versus adjuvant immunotherapy alone for high-risk resectable Stage III melanoma. However, the optimal regimen balancing efficacy and tolerability is unknown. T-cell immunoglobulin and ITIM domain (TIGIT) is a promising immune checkpoint whose therapeutic potential in Stage III melanoma is underexplored.

METHODS

In this phase II trial, patients with resectable, macroscopic Stage III melanoma received four 21-day neoadjuvant cycles of 1200 mg IV atezolizumab (anti-PD-L1) + 600 mg IV tiragolumab (anti-TIGIT), therapeutic lymph node dissection (TLND) and eight adjuvant cycles of atezolizumab. Primary endpoints were pathologic response and recurrence-free survival (RFS) after TLND in patients receiving adjuvant therapy; secondary and exploratory endpoints included adverse events (AEs), EFS and distant metastasis-free survival (DMFS).

RESULTS

Thirty-four patients initiated neoadjuvant atezolizumab/tiragolumab and were evaluable for AEs, pathologic response and EFS. 76.5 % had > 1 metastatic lymph node at baseline and 73.5 % were Stage IIIC. Thirty patients had per protocol TLND. Major pathologic responses (MPR, ≤10 % viable tumor) were observed in 16/34 patients (47.1 %). With 19.9 months median follow-up, 12-month EFS was 72.0 % (95 %CI 57.9-89.5 %), 12-month RFS was 73.3 % (95 %CI 56.9-94.5 %), and 12-month DMFS 86.0 % (95 %CI 72.2-100 %). 12-month RFS and DMFS for patients with an MPR were both 91.7 % (95 %CI: 77.3-100 %). Grade 3 + AEs at least possibly neoadjuvant treatment-related occurred in 2 patients (5.9 %).

CONCLUSION

Among patients with high-risk resectable Stage III melanoma, neoadjuvant atezolizumab/tiragolumab was a promising regimen with a favorable safety profile and warrants further study. A strategy to personalize neoadjuvant regimen selection is needed.

Для цитирования: Hieken Tina J, Zahrieh David, Flotte Thomas J, Dronca Roxana S, Domingo-Musibay Evidio, Nelson Garth D, Strand Carrie A, Kottschade Lisa A, Montane Heather N, Piltin Mara A, Chen Ruqin, McWilliams Robert R, Jakub James W, Khariwala Samir S, Dudek Arkadiusz Z, Johnson Jeffrey E, Markovic Svetomir N, Dimou Anastasios, Tasche Kendall K, Block Matthew S. NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.. European journal of cancer (Oxford, England : 1990). 2025. DOI: 10.1016/j.ejca.2025.115688.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.